|
KR20210018880A
|
|
Pharmaceutical composition comprising 2,4,6-trihydroxyacetophenone as a active ingredient for treating prostate cancer
|
|
WO2021080184A1
|
|
Small-sized, sustained release pharmaceutical composition comprising choline alfoscerate
|
|
WO2021080185A1
|
|
Sustained-release, small-sized orally administered preparation containing choline alfoscerate
|
|
KR20200015639A
|
|
Enteric coated formulation comprising fenofibric acid a or pharmaceutically acceptable salts thereof
|
|
KR20200121591A
|
|
Pharmaceutical Composition Comprising Aceclofenac and Method of Preparing Thereof
|
|
KR20200098120A
|
|
Method for Preparing Sustained Release Tablets Containing Levodropropizine
|
|
WO2019208898A1
|
|
Liquid syrup preparation containing choline alfoscerate
|
|
KR20190123664A
|
|
Liquid formulation comprising choline alfoscerate
|
|
KR20200020542A
|
|
Sustained release preparation of cilostazol
|
|
KR20200004178A
|
|
Pharmaceutical composition containing pelagonium sidoides extracts, and preparing method thereof
|
|
KR20190142809A
|
|
Pharma ceutical Composition Comprising Cilostazol and Statin derivatives
|
|
WO2019240310A1
|
|
Complex formulation comprising aceclofenac and esomeprazole and method of preparing same
|
|
KR20190135727A
|
|
Device for inhalation
|
|
KR20190123411A
|
|
Enteric coated formulation comprising fenofibric acid a or pharmaceutically acceptable salts thereof
|
|
KR20190119881A
|
|
A method for preparation of organic solvent-free lyophilized cyclophosphamide
|
|
KR20190085292A
|
|
Pharmaceutical composition comprising 2,4,6-trihydroxyacetophenone as a active ingredient for treating prostate cancer
|
|
KR20190071424A
|
|
Cored tablet comprising mosapride and rabeprazole
|
|
KR20190029997A
|
|
Sustained-release formulation comprising itopride using parameters for release control
|
|
KR20190029996A
|
|
Release controlled oral dosage form comprising itopride
|
|
KR20190029354A
|
|
Once a day oral dosage sustained-release formulation comprising itopride
|
